Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients
Authors:
- 1 December 1987
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 13 (6) , 393-406
Abstract
In this small study, the effect of aminoglutethimide on the disposition of oestrogens in women with advanced breast cancer was investigated using bolus injections of 4-[14C]-oestradiol and 6,7-[3H]-oestrone sulphate, alone or in combination. No alterations in oestrogen disposition were seen after short term (6 hours) aminoglutethimide administration. During long term (3 weeks to 8 months) aminoglutethimide treatment mean 4-[14C]-oestradiol clearance was not changed. 14C-Oestrone sulphate AUC was reduced by 43% at a low dose of aminoglutethimide (125mg twice daily) and by 65% at a high dose (250mg 4 times daily) with hydrocortisone acetate 25mg twice daily. The oestrone sulphate terminal elimination rate constant (λz) was concurrently increased (mean of 46 and 79%, respectively, with the 2 dosage regimens). A possible increase in oestrone sulphate clearance during long term treatment was tested for by injecting 6,7-[3H]-oestrone sulphate. These studies revealed a marked increase (mean 104%) in oestrone sulphate clearance in patients receiving the high dose aminoglutethimide schedule. Following injection of 4-[14C]-oestradiol plus 6,7-[3H]-oestrone sulphate, the fraction of 4-[14C]-oestradiol metabolised to oestrone sulphate was found to be reduced in all patients (mean 13%). A mean increase of 80% in the urinary excretion of 14C-oestriol was observed after 4-[14C]-oestradiol administration. Our results, although preliminary, suggest that aminoglutethimide is a potent inducer of aminoglutethimide metabolism, thereby producing a significant reduction in plasma bioavailability of oestrone sulphate. These effects may have a role in the action of aminoglutethimide, a finding which warrants further investigation.Keywords
This publication has 51 references indexed in Scilit:
- Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancerEuropean Journal of Cancer and Clinical Oncology, 1986
- Single-Dose and Steady-State Pharmacokinetics of AminoglutethimideClinical Pharmacokinetics, 1985
- Conjugated and unconjugated plasma oestrogens in men with chronic alcoholism and in normal menJournal of Steroid Biochemistry, 1984
- Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A reviewBreast Cancer Research and Treatment, 1981
- Interaction between Estrogen and Dilantin in a Menopausal WomanNew England Journal of Medicine, 1981
- Conjugated and unconjugated plasma oestrogens—oestrone, oestradiol and oestriol—in normal human malesThe Journal of Steroid Biochemistry and Molecular Biology, 1980
- Induction of testosterone 16β-hydroxylase in rat liver microsomes by phenobarbital pretreatmentBiochemical and Biophysical Research Communications, 1980
- Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.Journal of Clinical Investigation, 1980
- Serum Aminoglutethimide Levels: Studies of Serum Half‐Life, Clearance, and Patient ComplianceThe Journal of Clinical Pharmacology, 1979
- Alterations of estrogen metabolism in systemic lupus erythematosusArthritis & Rheumatism, 1979